TriPath PREPmate Approval Lifts Stock 60%; OTC Index Outperforms Nasdaq
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of TriPath Imaging's PREPmate automated accessory for the AutoCyte PREP thin-layer sample preparation system combined with strong first-quarter earnings helped boost the company's stock price 60% in May. The issue advanced 3.27 points to close the month at 8.77.